A review on the efficacy and the tolerability of Quetiapine ( Seroquel ), either as monotherapy or combination therapy, for acute bipolar depression, was done.
Researchers have included all randomized, controlled trials ( RCTs ) comparing Quetiapine with other treatments, including placebo, in patients with acute bipolar depression ( bipolar I or II disorder, major depressive episode ).
The primary outcome was the change scores of depression rating scales.
Eleven RCTs ( n=3,488 ) were included. Two of them were conducted in children and adolescents. The change in depression scores was significantly greater in the Quetiapine group compared with the placebo group ( mean difference, [ MD ]: -4.66 ).
The significant difference was observed from week 1.
Compared with placebo, Quetiapine had higher incidence rates of extrapyramidal side effects, sedation, somnolence, dizziness, fatigue, constipation, dry mouth, increased appetite, and weight gain but lower risks of treatment-emergent mania and headache.
Quetiapine treatment was associated with significant improvement of clinical global impression, quality of life, sleep quality, anxiety, and functioning.
In conclusion, Quetiapine monotherapy is effective for acute bipolar depression and the prevention of mania / hypomania switching.
Its common adverse effects are extrapyramidal side effects, sedation, somnolence, dizziness, fatigue, constipation, dry mouth, increased appetite, and weight gain.
The lower risk of headache in Quetiapine-treated patients with acute bipolar depression should be further investigated.
The evidence for the use of Quetiapine combined with mood stabilizers in children and adolescents with acute bipolar depression is too small to support the clinical practice. ( Xagena )
Suttajit S et al, Drug Des Devel Ther 2014;8:827-838